The recent FDA approval of Alhemo (concizumab-mtci) in the U.S. for those 12 years and older with hemophilia A or B without inhibitors could reshape treatment for many living with these rare bleeding disorders.

The approval, announced July 31 , expands the drug’s indication beyond its earlier approval in December 2024 for patients with inhibitors , offering a once-daily subcutaneous injection in place of traditional intravenous (IV) infusions.

For those with hemophilia, prophylaxis—a preventive therapy to reduce the frequency of bleeding episodes—has long required IV administration of missing clotting factors. While it’s effective, IV therapy can be challenging for patients and caregivers because of the need to access the veins of patients, infusion time and the skills required to per

See Full Page